Skip to main content
AMCP Nexus 2024 Main banner
Back

Drugs, Diseases, and the Managed Care Impact

(D4) Maximizing Utilization and Continuity of Care: Advancing Adalimumab Biosimilar Adoption in Managed Care

Wednesday, October 16, 2024
10:15 AM – 11:30 AM PT
Location: 114
CPE
ACPE UAN:0233-0000-24-056-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
The adalimumab market has expanded significantly over the past couple of years. After initially experiencing slower-than-expected utilization, it has recently experienced more growth. Integrating these biosimilars into formularies comes with their own challenges and complexities, from adapting workflow to effectively communicating with providers and patients.

In this session, faculty will discuss strategies to overcome these integration challenges to optimize formulary management and enhance communication and education for both providers and patients. Additionally, patients will gain insights into overcoming obstacles and implementing best practices to ensure a seamless adoption of adalimumab biosimilars.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Review the impact of the expanding adalimumab market on managed care.
  2. Identify the challenges and complexities of integrating adalimumab biosimilars into the formulary management workflow through real-world case examples.
  3. Discuss communication strategies and innovative approaches for integrating adalimumab biosimilars into clinical practice without delaying patient care.